B-cell acute lymphoblastic leukemia pediatric · 7 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Imatinib-based consolidation Variant #01 | BCR::ABL1 | R 11 361 | 28d | — | — | — | — | — |
Etoposide and TBI, then allo HSCT Variant #03 | — | R 6 278 | — | — | — | — | — | — |
Etoposide, Ifosfamide, Imatinib Variant #01 | BCR::ABL1 | R 6 072 | 21d | — | — | — | — | — |
AALL0232 consolidation Variant #01 | — | R 5 050 | 50d | — | — | — | — | — |
Augmented BFM consolidation Variant #01 | — | R 5 050 | 63d | — | — | — | — | — |
Mercaptopurine and Vincristine Variant #01 | — | R 3 787 | 28d | — | — | — | — | — |
Cyclophosphamide and TBI, then allo HSCT Variant #01 | — | R 1 176 | — | — | — | — | — | — |
7 of 7 regimens shown